Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
… Officer role, with leadership oversight of Axiomer ® RNA-editing platform technology John Maraganore, PhD, former … provide strategic oversight of ProQR’s proprietary Axiomer RNA-editing platform technology. He is the scientific … including further building out the Company’s Axiomer RNA-editing technology as a value-generating platform. Smital …